The EPS miss and absence of near-term revenue catalysts suggest limited upside in the near term. Traders should focus on upcoming MZE829 HORIZON data in late 2026/early 2027 and MZE782 CIPheR data in 2027 as key pipeline catalysts. The strong cash runway into 2029 reduces financing risk but does not offset the lack of revenue visibility.
Price Chart
Executive Summary
Maze Therapeutics reported Q2 2026 EPS of -$0.76, missing consensus of -$0.70 by 8.6%, with no license revenue for the quarter. The company highlighted strong cash position of $494.9M and ongoing Phase 2 trials for MZE829 and MZE782, with key data readouts expected in late 2026/2027. The EPS miss and lack of near-term revenue catalysts offset pipeline progress, resulting in a neutral-to-mixed outlook given the clinical-stage nature of the company.
Key Financial Metrics
Key Facts
- Q2 2026 EPS of -$0.76 missed consensus of -$0.70 (8.6% miss)
- No license revenue in Q2 2026 vs $20M in Q1 2026 from Shionogi milestone
- Cash, cash equivalents and marketable securities of $494.9M as of June 30, 2026, providing runway into 2029
- Phase 2 HORIZON trial of MZE829 enrollment on track; updated data expected late 2026/early 2027
- Phase 2 CIPheR trial of MZE782 in PKU initiated; topline data expected in 2027
- Net loss of $44.7M in Q2 2026 vs $33.7M in Q2 2025, driven by higher R&D and G&A expenses
Financial Impact
EPS miss of 8.6% vs consensus; no revenue in Q2; net loss widened to $44.7M from $33.7M YoY
Risk Factors
- Clinical trial delays or negative data for MZE829 or MZE782
- No near-term revenue sources; reliance on pipeline milestones
- Higher R&D and G&A expenses driving increased net losses
- Competition from other APOL1 inhibitors and PKU/CKD therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343141 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | Insider Cluster | $26.37 $24.23 | ▼ −8.12% | ▼ −7.00% | $26.69 (+1.20%) |
Sep 4, 2026 27d ago | Insider Cluster | $26.37 $24.23 | ▼ −8.12% | ▼ −7.00% | $26.69 (+1.20%) |
Sep 3, 2026 29d ago | Insider Cluster | $25.87 $24.60 | ▼ −4.91% | ▼ −3.76% | $26.69 (+3.16%) |
Sep 2, 2026 29d ago | 144 | $25.87 $24.60 | ▼ −4.91% | ▼ −3.76% | $26.69 (+3.16%) |
Sep 1, 2026 4w ago | 144 | $26.72 $24.82 | ▼ −7.11% | ▼ −6.15% | $26.69 (−0.12%) |
Aug 17, 2026 6w ago | 3 | $29.13 $30.42 | ▲ +4.43% | ▲ +4.63% | $26.69 (−8.38%) |
Aug 11, 2026 7w ago | Press Release | $27.53 $29.75 | ▲ +8.06% | ▲ +8.51% | $26.69 (−3.06%) |
Aug 7, 2026 8w ago | Institutional Cluster | $28.65 $27.18 | ▼ −5.13% | ▼ −5.53% | $26.69 (−6.85%) |
Aug 5, 2026 8w ago | Insider Cluster | $27.81 $27.53 | ▼ −1.01% | ▼ −1.36% | $26.69 (−4.04%) |
Jul 2, 2026 13w ago | Insider Cluster | $31.26 $32.42 | ▲ +3.71% | ▲ +2.78% | $26.69 (−14.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access